BiotechnologyClinical TrialsHuman Trials November 4, 2026 FDA to review uniQure’s BLA for Huntington’s gene therapy By Salong Debbarma The submission has been granted Priority Review, setting a target action date of 1 May 2027 under the Prescription Drug User Fee Act (PDUFA). The regulator also indicated
Infectious Disease November 3, 2026 Bavarian Nordic secures four-year UK vaccine supply deal By PBR Staff Writer The deal for the vaccine was awarded through the UK Health Security Agency. Under the contract, the company will deliver scheduled shipments of MVA-BN across the term. The
Drug Manufacturing November 2, 2026 Pelthos and Castle Creek plan merger to target skin diseases By PBR Staff Writer This transaction would add Castle Creek’s gene-modified cell therapy candidate D-Fi to Pelthos’s dermatology portfolio. The combined company would operate as Pelthos Therapeutics and continue trading on the
Packaging & Supply ChainStoragePharmaceuticals and Healthcare October 30, 2026 Glenmark opens Allentown distribution hub in US By Salong Debbarma Set across a 6.5-acre site, the facility functions as the company’s sole distribution centre in the US. A workforce of 45 members handles administration, quality control, and general
BiotechnologyOncology October 26, 2026 Pathos AI completes $237m Series E round to expand oncology pipeline By Salong Debbarma The transaction values the US-based biotechnology company at approximately $3bn post-money. Bristol Myers Squibb (BMS) led the funding round, with further capital provided by existing investors. Pathos AI
BiotechnologyPharmaceuticals and Healthcare October 23, 2026 Celltrion and Kaigene sign $580m licence deal for KG013 By Salong Debbarma The financial package includes an upfront payment alongside milestone payments tied to specific development, regulatory, and commercial targets. Royalties on net sales remain separate from the package. Kaigene
RegulationApprovalsOncology October 22, 2026 MSD’s Keytruda and Padcev combination receives EC approval By Salong Debbarma The clearance permits the therapies to be administered before radical cystectomy as neoadjuvant therapy and continued following surgery as adjuvant treatment. Applicable to patients irrespective of cisplatin eligibility,
BiotechnologyDrug DiscoveryResearch & Development October 21, 2026 Sanofi and ScionxBio partner on mRNA therapies By Salong Debbarma Under the arrangement, the companies will create extended-exposure formulations of selected mRNA candidates from Sanofi by applying ScionxBio’s TERA technology. The partnership divides research and clinical duties between
BiotechnologyPharmaceuticals and Healthcare October 19, 2026 Estuary secures $103m to advance kidney disease gene therapies By Salong Debbarma The capital will fund clinical proof-of-concept testing for the biotechnology company’s lead gene therapy candidates, EST-101 and EST-201, whilst advancing its platform for direct kidney delivery. The total
BiotechnologyDrug DiscoveryResearch & Development October 16, 2026 Transcripta Bio, Mayo Clinic join force on ALS therapies By Salong Debbarma The initiative centres on creating a high-resolution, patient-derived molecular map of the fatal neurodegenerative disorder, which currently has few effective therapies. Under the terms of the agreement, Mayo